Chugai Pharmaceutical Co.

Chugai Pharmaceutical Co., Ltd. (中外製薬株式会社, Chūgai Seiyaku kabushiki gaisha) is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014.^[1] The company is headquartered in Tokyo. Osamu Nagayama is the current^{[as of?]} representative director and chairman. Tatsuro Kosaka is the current^{[as of?]} representative director, president and CEO.

Chugai Pharmaceutical Co., Ltd.

Headquarters in Nihonbashi Mitsui Tower
Native name	中外製薬株式会社
Romanized name	Chūgai Seiyaku kabushiki gaisha
Company type	Public KK
Traded as	TYO: 4519 Nikkei 225 component
Industry	Pharmaceutical Industry, Business import, production and development of drugs for medical sales
Founded	March 8, 1943; 82 years ago (1943-03-08)
Headquarters	Nihonbashi Mitsui Tower, Nihonbashi Muromachi 2-1-1, Chūō, Tokyo On the registration Headquarter: Tokyo Kita (Tokyo)
Key people	Osamu Nagayama - Chairman and Tatsuro Kosaka - CEO
Revenue	72.9 billion capital of 47 million yen. Standalone sales of 329.2 billion yen and 344.8 billion yen consolidated (December 2007)
Parent	Hoffmann-La Roche (61.62%)
Website	www.chugai-pharm.co.jp (in Japanese)

History

Timeline

This is a timeline of important events of Chugai Pharmaceutical.^[2]

• 1925: Juzo Ueno founded Chugai Shinyaku Co. Ltd. and started importing and selling medicines
• 1927: Start of the first own production
• 1930: Salobrocanon, an analgesic (pain reliever ) and antipyretic, is launched
• 1937: Calcium bromide production begins
• 1943: Name changed to Chugai Pharmaceutical Co., Ltd. based in Tokyo
• 1944: Acquisition of Matsunaga Pharmaceutical Ltd. and construction of a plant in Matsunaga
• 1945: The headquarters, the factories in Ikebukuro, Sakai and Takada were destroyed in World War II, the headquarters were relocated to Takada, the factory in Takada was rebuilt
• 1946: Construction of the plant in Kamagiishi
• 1951: Guronsan, a drug to detoxify and restore liver function, is launched
• 1952: Varsan, a perspiration insecticide, is launched
• 1955: Chugai became a public company.
• 1956: The stock is listed on the Tokyo Stock Exchange
• 1957: Construction of the Ukima plant
• 1960: Establishment of a research center (Takada Research Laboratory, Tokyo)
• 1967: Foundation of Fukushima Kasai Co Ltd.
• 1961 – Developed patents for synthesis of vitamin A
• 1969: The name of Fukushima Kasai Co Ltd. is changed to Eiko Kasei Co Ltd., after the merger of Fukushima Kasai Co Ltd. and Fukuma Kasau Co. Ltd.
• 1971: Construction of the factory in Fujieda
• 1975: Picibanil, a cancer drug, is launched
• 1982: Opening of a branch in New York
• 1986: Opening of a branch in London
• 1989: Acquisition of Gen-Probe Incorporated (USA)
• 1990: Epogin launched
• 1995 – Released acute promyelocytic sphere of leukemia drug treatment Vesanoid
• 1996 – Released anti-viral chemotherapeutic agent Hivid (HIV reverse transcriptase inhibitor)
• 1997 – Released HIV protease inhibitor Invirase
• 1999 – Released immunosuppressive agent Cellcept
• 2000 – Released antiemetic drug Kytril, developed to combat the side effects of chemotherapy
• 2001 – Produced anti-influenza virus Tamiflu (Roche)
• 2002: Start of the alliance with Roche
• 2003: Xeloda, a cancer drug, is launched
• 2005: Actemra launched
• 2007: Copegus, an antiviral, Avastin, a cancer drug, and Tarceva, a cancer drug launched
• 2011 – Produced Actemra, a human IL-6 receptor monoclonal antibody for rheumatoid arthritis
• 2014: Launch of Kadcyla, a cancer drug, Chugai Pharma China Co Ltd. founded
• 2015 – In March the company announced it would co-commercialise Athersys's stem cell therapy for ischemic strokes in Japan. The deal could yield upwards of US$205 million.^[3]
• 2016: Cooperation between Osaka University and Chugai
• 2018: Tecentriq, a cancer drug, is launched
• 2020 – FDA approved satralizumab (Enspryng) for treatment of the orphan disease neuromyelitis optica^[4]

See also

• Biotech and pharmaceutical companies in the New York metropolitan area